The Clinical Investigations Department at BC Cancer was established to be the central point of contact for investigators wanting to undertake clinical research at BC Cancer. 

We are putting together a team of dedicated and recognized experts to help guide investigators and study teams to achieve the highest quality research.  The goals of the department are to improve the quality and productivity of clinical research at BC Cancer while encouraging a culture of innovation, responsibility and accountability.  The Clinical Investigations Department is committed to ensuring BC Cancer clinical research is operationally efficient and of high quality.  We will achieve this by standardizing practices across the province, providing comprehensive education programs and quality and metrics reporting and administrative support for clinician-investigators.

From Research to Treatment

Many of the treatments we have in Canada today are available thanks to people who volunteer to take part in a clinical trial​.  

News & Events

BC Cancer researchers awarded in Michael Smith Health Research BC 2024 Scholar and Health Professional-Investigator competition

Five BC Cancer researchers are 2024 recipients of the Michael Smith Health Research BC’s Scholar and Health Professional-Investigator competition, receiving new funding to conduct critical research, develop innovative treatments, and translate their findings into practices that benefit people across BC.

Scholar award recipients 

Scholar awards support early career health researchers, allowing them to form their own research teams and research programs. Recipients dedicate 75 per cent of their time to health research activities. 

Scientists discover high-risk form of endometrial cancer — and how to test for it — using AI

​Dr. Jessica McAlpine, surgeon-scientist, BC Cancer and Vancouver General Hospital and professor and Dr. Chew Wei Chair in Gynaecologic Oncology at UBC

Using artificial intelligence (AI) to spot patterns across thousands of cancer cell images, the researchers have pinpointed a distinct subset of endometrial cancer that puts patients at much greater risk of recurrence and death, but would otherwise go unrecognized by traditional pathology and molecular diagnostics.

Back to top